Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
НПВП в лечении пациенток с первичной дисменореей
НПВП в лечении пациенток с первичной дисменореей
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Первичная дисменорея является одной из наиболее частых форм нарушения менструального цикла в молодом возрасте. Нередко она приводит к утрате трудоспособности пациенток на несколько дней и требует назначения эффективных и быстродействующих средств. Первой линией терапии при первичной дисменорее признаны нестероидные противовоспалительные препараты (НПВП). При стойком нарушении менструальной функции, приводящем к повторяющимся эпизодам боли, возможно назначение комбинированных гормональных контрацептивов. Эффективность альтернативных методов лечения хотя и подтверждена рядом исследователей, однако уступает традиционным подходам. Согласно последним данным высокую эффективность в лечении первичной дисменореи показал НПВП ибупрофен в дозе 400 мг.
Ключевые слова: первичная дисменорея, НПВП, ибупрофен 400 мг.
Key words: primary dysmenorrhea, NSAIDs, ibuprofen 400 mg.
Ключевые слова: первичная дисменорея, НПВП, ибупрофен 400 мг.
________________________________________________
Key words: primary dysmenorrhea, NSAIDs, ibuprofen 400 mg.
Полный текст
Список литературы
1. Umland EM, Weinstein LC, Buchanan EM. Menstruation-related disorders. Pharmacotherapy: A Pathophysiologic Approach. 8th ed. New York, NY: McGraw-Hill; 2011.
2. Lefebvre G, Pinsonneault O, Antao V et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 2005; 27: 1117–46.
3. Hall JE. Menstrual disorders and pelvic pain. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill, 2012.
4. Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. J Adolesc Health Care 1988; 9: 398–402.
5. Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 1997; 151: 905–13.
6. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981; 68: 661–4.
7. Iglesias EA, Coupey SM. Menstrual cycle abnormalities. Diagnosis and management. Adolesc Med 1999; 10 (2): 255–73.
8. Coco AS. Primary dysmenorrhea. Am Fam Physician 1999; 60 (2): 489–96.
9. Banikarim C, Middleman AB. Primary dysmenorrhea in adolescents. Up To Date Online.
10. Emans SJ, Laufer RL, Goldstein DP. Pediatric & adolescent gynecology. 5th ed. Philadelphia. Lippincott, Williams & Wilkins, 2005; p. 417–22.
11. Twigg J. Dysmenorrhoea. Curr Obstet Gynaecol 2002; 12: 341–5.
12. Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996; 87 (1): 55–8.
13. Pullon S, Reinken J, Sparrow M. Prevalence of dysmenorrhoea in Wellington women. N Z Med J 1988; 101 (839): 52–4.
14. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 1990; 97 (7): 588–94.
15. Harlow S, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol 1996; 103 (11): 1134–42.
16. Kritz-Silverstein D, Wingard DL, Garland FC. The association of behavior and lifestyle factors with menstrual symptoms. J Womens Health Gend Based Med 1999; 8 (9): 1185–93.
17. Alonso C, Coe CL. Disruptions of social relationships accentuate the association between emotional distress and menstrual pain in young women. Health Psychol 2001; 20 (6): 411–6.
18. Purcell KJ, Taylor RN. Disorders of the female reproductive tract. Pathophysiology of Disease: An Introduction to Clinical Medicine. 6th ed. New York, NY: McGraw-Hill, 2010.
19. Dmitrovic R, Kunselman AR, Legro RS. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 2012; 119: 1143–50.
20. Zhu X, Proctor M, Bensoussan A et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2008; 2: CD005288.
21. Патофизиология. Учебник. В 2 т. Под ред. В.В.Новицкго, Е.Д.Гольдберг, О.И.Уразовой. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2012.
22. Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev 2010; 2: CD004142.
23. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; 1: CD001751.
24. SOGC clinical practice guideline. JOGC Décembre 2005; 169: 1117–30.
25. Barbieri RL. Primary dysmenorrhea in adults. Up To Date Online.
26. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998; 105: 780–9.
27. De Mello NR, Baracat EC, Tomaz G et al. Double-blind study to evaluate efficacy and safety of meloxicam 7,5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 2004; 83: 667–73.
28. Henry D et al. BMJ 1996; 312: 1563–6.
29. Castellasgue J et al. Drug Safety 2012; 35: 1127–46.
30. Debski R. Comparative efficacy and tolerability of drotaverine 80 mg and ibuprofen 400 mg in patients with primary dysmenorrhoea – protocol DOROTA. Ginekol Pol 2007; 78 (12): 933–8.
31. Hauksson A, Ekström P, Juchnicka E et al. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1989; 68 (1): 31–4.
32. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; 4: CD002120.
33. Dawood MY. Primary Dysmenorrhea. Advances in Pathogenesis and Management. Obstet Gynecol 2006; 108: 428–41.
34. Клиническая фармакология нестероидных противовоспалительных средств. Под ред. Ю.Д.Игнатова, В.Г.Кукеса, В.И.Мазурова. М.: ГЭОТАР-Медиа, 2010.
35. Marchini M et al. International J Clin Pharm Therap 1995; 9: 491–7.
36. Colombo F et al. Comparative evaluation of the efficacy of naproxen sodium and ibuprofen in the treatment of primarydysmenorrhea. Ann Ost Ginecol Med Perinat 1990; 111 (3): 205–8.
37. Инструкция по медицинскому применению препарата Нурофен Экспресс Леди.
38. American College of Obstetricians and Gynecologists (ACOG). Noncontraceptive uses of hormonal contraceptives. Washington (DC): American College of Obstetricians and Gynecologists (ACOG), 2010.
2. Lefebvre G, Pinsonneault O, Antao V et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 2005; 27: 1117–46.
3. Hall JE. Menstrual disorders and pelvic pain. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill, 2012.
4. Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. J Adolesc Health Care 1988; 9: 398–402.
5. Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 1997; 151: 905–13.
6. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981; 68: 661–4.
7. Iglesias EA, Coupey SM. Menstrual cycle abnormalities. Diagnosis and management. Adolesc Med 1999; 10 (2): 255–73.
8. Coco AS. Primary dysmenorrhea. Am Fam Physician 1999; 60 (2): 489–96.
9. Banikarim C, Middleman AB. Primary dysmenorrhea in adolescents. Up To Date Online.
10. Emans SJ, Laufer RL, Goldstein DP. Pediatric & adolescent gynecology. 5th ed. Philadelphia. Lippincott, Williams & Wilkins, 2005; p. 417–22.
11. Twigg J. Dysmenorrhoea. Curr Obstet Gynaecol 2002; 12: 341–5.
12. Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996; 87 (1): 55–8.
13. Pullon S, Reinken J, Sparrow M. Prevalence of dysmenorrhoea in Wellington women. N Z Med J 1988; 101 (839): 52–4.
14. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 1990; 97 (7): 588–94.
15. Harlow S, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol 1996; 103 (11): 1134–42.
16. Kritz-Silverstein D, Wingard DL, Garland FC. The association of behavior and lifestyle factors with menstrual symptoms. J Womens Health Gend Based Med 1999; 8 (9): 1185–93.
17. Alonso C, Coe CL. Disruptions of social relationships accentuate the association between emotional distress and menstrual pain in young women. Health Psychol 2001; 20 (6): 411–6.
18. Purcell KJ, Taylor RN. Disorders of the female reproductive tract. Pathophysiology of Disease: An Introduction to Clinical Medicine. 6th ed. New York, NY: McGraw-Hill, 2010.
19. Dmitrovic R, Kunselman AR, Legro RS. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 2012; 119: 1143–50.
20. Zhu X, Proctor M, Bensoussan A et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2008; 2: CD005288.
21. Патофизиология. Учебник. В 2 т. Под ред. В.В.Новицкго, Е.Д.Гольдберг, О.И.Уразовой. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2012.
22. Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev 2010; 2: CD004142.
23. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; 1: CD001751.
24. SOGC clinical practice guideline. JOGC Décembre 2005; 169: 1117–30.
25. Barbieri RL. Primary dysmenorrhea in adults. Up To Date Online.
26. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998; 105: 780–9.
27. De Mello NR, Baracat EC, Tomaz G et al. Double-blind study to evaluate efficacy and safety of meloxicam 7,5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 2004; 83: 667–73.
28. Henry D et al. BMJ 1996; 312: 1563–6.
29. Castellasgue J et al. Drug Safety 2012; 35: 1127–46.
30. Debski R. Comparative efficacy and tolerability of drotaverine 80 mg and ibuprofen 400 mg in patients with primary dysmenorrhoea – protocol DOROTA. Ginekol Pol 2007; 78 (12): 933–8.
31. Hauksson A, Ekström P, Juchnicka E et al. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1989; 68 (1): 31–4.
32. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; 4: CD002120.
33. Dawood MY. Primary Dysmenorrhea. Advances in Pathogenesis and Management. Obstet Gynecol 2006; 108: 428–41.
34. Клиническая фармакология нестероидных противовоспалительных средств. Под ред. Ю.Д.Игнатова, В.Г.Кукеса, В.И.Мазурова. М.: ГЭОТАР-Медиа, 2010.
35. Marchini M et al. International J Clin Pharm Therap 1995; 9: 491–7.
36. Colombo F et al. Comparative evaluation of the efficacy of naproxen sodium and ibuprofen in the treatment of primarydysmenorrhea. Ann Ost Ginecol Med Perinat 1990; 111 (3): 205–8.
37. Инструкция по медицинскому применению препарата Нурофен Экспресс Леди.
38. American College of Obstetricians and Gynecologists (ACOG). Noncontraceptive uses of hormonal contraceptives. Washington (DC): American College of Obstetricians and Gynecologists (ACOG), 2010.
2. Lefebvre G, Pinsonneault O, Antao V et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 2005; 27: 1117–46.
3. Hall JE. Menstrual disorders and pelvic pain. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill, 2012.
4. Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. J Adolesc Health Care 1988; 9: 398–402.
5. Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 1997; 151: 905–13.
6. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981; 68: 661–4.
7. Iglesias EA, Coupey SM. Menstrual cycle abnormalities. Diagnosis and management. Adolesc Med 1999; 10 (2): 255–73.
8. Coco AS. Primary dysmenorrhea. Am Fam Physician 1999; 60 (2): 489–96.
9. Banikarim C, Middleman AB. Primary dysmenorrhea in adolescents. Up To Date Online.
10. Emans SJ, Laufer RL, Goldstein DP. Pediatric & adolescent gynecology. 5th ed. Philadelphia. Lippincott, Williams & Wilkins, 2005; p. 417–22.
11. Twigg J. Dysmenorrhoea. Curr Obstet Gynaecol 2002; 12: 341–5.
12. Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996; 87 (1): 55–8.
13. Pullon S, Reinken J, Sparrow M. Prevalence of dysmenorrhoea in Wellington women. N Z Med J 1988; 101 (839): 52–4.
14. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 1990; 97 (7): 588–94.
15. Harlow S, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol 1996; 103 (11): 1134–42.
16. Kritz-Silverstein D, Wingard DL, Garland FC. The association of behavior and lifestyle factors with menstrual symptoms. J Womens Health Gend Based Med 1999; 8 (9): 1185–93.
17. Alonso C, Coe CL. Disruptions of social relationships accentuate the association between emotional distress and menstrual pain in young women. Health Psychol 2001; 20 (6): 411–6.
18. Purcell KJ, Taylor RN. Disorders of the female reproductive tract. Pathophysiology of Disease: An Introduction to Clinical Medicine. 6th ed. New York, NY: McGraw-Hill, 2010.
19. Dmitrovic R, Kunselman AR, Legro RS. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 2012; 119: 1143–50.
20. Zhu X, Proctor M, Bensoussan A et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2008; 2: CD005288.
21. Патофизиология. Учебник. В 2 т. Под ред. В.В.Новицкго, Е.Д.Гольдберг, О.И.Уразовой. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2012.
22. Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev 2010; 2: CD004142.
23. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; 1: CD001751.
24. SOGC clinical practice guideline. JOGC Décembre 2005; 169: 1117–30.
25. Barbieri RL. Primary dysmenorrhea in adults. Up To Date Online.
26. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998; 105: 780–9.
27. De Mello NR, Baracat EC, Tomaz G et al. Double-blind study to evaluate efficacy and safety of meloxicam 7,5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 2004; 83: 667–73.
28. Henry D et al. BMJ 1996; 312: 1563–6.
29. Castellasgue J et al. Drug Safety 2012; 35: 1127–46.
30. Debski R. Comparative efficacy and tolerability of drotaverine 80 mg and ibuprofen 400 mg in patients with primary dysmenorrhoea – protocol DOROTA. Ginekol Pol 2007; 78 (12): 933–8.
31. Hauksson A, Ekström P, Juchnicka E et al. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1989; 68 (1): 31–4.
32. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; 4: CD002120.
33. Dawood MY. Primary Dysmenorrhea. Advances in Pathogenesis and Management. Obstet Gynecol 2006; 108: 428–41.
34. Клиническая фармакология нестероидных противовоспалительных средств. Под ред. Ю.Д.Игнатова, В.Г.Кукеса, В.И.Мазурова. М.: ГЭОТАР-Медиа, 2010.
35. Marchini M et al. International J Clin Pharm Therap 1995; 9: 491–7.
36. Colombo F et al. Comparative evaluation of the efficacy of naproxen sodium and ibuprofen in the treatment of primarydysmenorrhea. Ann Ost Ginecol Med Perinat 1990; 111 (3): 205–8.
37. Инструкция по медицинскому применению препарата Нурофен Экспресс Леди.
38. American College of Obstetricians and Gynecologists (ACOG). Noncontraceptive uses of hormonal contraceptives. Washington (DC): American College of Obstetricians and Gynecologists (ACOG), 2010.
________________________________________________
2. Lefebvre G, Pinsonneault O, Antao V et al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can 2005; 27: 1117–46.
3. Hall JE. Menstrual disorders and pelvic pain. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill, 2012.
4. Johnson J. Level of knowledge among adolescent girls regarding effective treatment for dysmenorrhea. J Adolesc Health Care 1988; 9: 398–402.
5. Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med 1997; 151: 905–13.
6. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics 1981; 68: 661–4.
7. Iglesias EA, Coupey SM. Menstrual cycle abnormalities. Diagnosis and management. Adolesc Med 1999; 10 (2): 255–73.
8. Coco AS. Primary dysmenorrhea. Am Fam Physician 1999; 60 (2): 489–96.
9. Banikarim C, Middleman AB. Primary dysmenorrhea in adolescents. Up To Date Online.
10. Emans SJ, Laufer RL, Goldstein DP. Pediatric & adolescent gynecology. 5th ed. Philadelphia. Lippincott, Williams & Wilkins, 2005; p. 417–22.
11. Twigg J. Dysmenorrhoea. Curr Obstet Gynaecol 2002; 12: 341–5.
12. Jamieson DJ, Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996; 87 (1): 55–8.
13. Pullon S, Reinken J, Sparrow M. Prevalence of dysmenorrhoea in Wellington women. N Z Med J 1988; 101 (839): 52–4.
14. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol 1990; 97 (7): 588–94.
15. Harlow S, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol 1996; 103 (11): 1134–42.
16. Kritz-Silverstein D, Wingard DL, Garland FC. The association of behavior and lifestyle factors with menstrual symptoms. J Womens Health Gend Based Med 1999; 8 (9): 1185–93.
17. Alonso C, Coe CL. Disruptions of social relationships accentuate the association between emotional distress and menstrual pain in young women. Health Psychol 2001; 20 (6): 411–6.
18. Purcell KJ, Taylor RN. Disorders of the female reproductive tract. Pathophysiology of Disease: An Introduction to Clinical Medicine. 6th ed. New York, NY: McGraw-Hill, 2010.
19. Dmitrovic R, Kunselman AR, Legro RS. Continuous compared with cyclic oral contraceptives for the treatment of primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 2012; 119: 1143–50.
20. Zhu X, Proctor M, Bensoussan A et al. Chinese herbal medicine for primary dysmenorrhoea. Cochrane Database Syst Rev 2008; 2: CD005288.
21. Патофизиология. Учебник. В 2 т. Под ред. В.В.Новицкго, Е.Д.Гольдберг, О.И.Уразовой. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2012.
22. Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev 2010; 2: CD004142.
23. Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010; 1: CD001751.
24. SOGC clinical practice guideline. JOGC Décembre 2005; 169: 1117–30.
25. Barbieri RL. Primary dysmenorrhea in adults. Up To Date Online.
26. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol 1998; 105: 780–9.
27. De Mello NR, Baracat EC, Tomaz G et al. Double-blind study to evaluate efficacy and safety of meloxicam 7,5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 2004; 83: 667–73.
28. Henry D et al. BMJ 1996; 312: 1563–6.
29. Castellasgue J et al. Drug Safety 2012; 35: 1127–46.
30. Debski R. Comparative efficacy and tolerability of drotaverine 80 mg and ibuprofen 400 mg in patients with primary dysmenorrhoea – protocol DOROTA. Ginekol Pol 2007; 78 (12): 933–8.
31. Hauksson A, Ekström P, Juchnicka E et al. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea. Acta Obstet Gynecol Scand 1989; 68 (1): 31–4.
32. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev 2009; 4: CD002120.
33. Dawood MY. Primary Dysmenorrhea. Advances in Pathogenesis and Management. Obstet Gynecol 2006; 108: 428–41.
34. Клиническая фармакология нестероидных противовоспалительных средств. Под ред. Ю.Д.Игнатова, В.Г.Кукеса, В.И.Мазурова. М.: ГЭОТАР-Медиа, 2010.
35. Marchini M et al. International J Clin Pharm Therap 1995; 9: 491–7.
36. Colombo F et al. Comparative evaluation of the efficacy of naproxen sodium and ibuprofen in the treatment of primarydysmenorrhea. Ann Ost Ginecol Med Perinat 1990; 111 (3): 205–8.
37. Инструкция по медицинскому применению препарата Нурофен Экспресс Леди.
38. American College of Obstetricians and Gynecologists (ACOG). Noncontraceptive uses of hormonal contraceptives. Washington (DC): American College of Obstetricians and Gynecologists (ACOG), 2010.
Авторы
В.В.Коренная
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
ГБОУ ДПО Российская медицинская академия последипломного образования Минздрава России, Москва
________________________________________________
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.